Gene test could sharpen leukemia risk forecasts
NCT ID NCT02756962
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 23 times
Summary
This study looks at whether checking for leukemia-related gene mutations after initial treatment can help predict which patients will stay cancer-free. About 107 adults aged 18-60 with intermediate-risk acute myeloid leukemia (AML) are being followed. The goal is to see if those whose mutations disappear have better survival than expected, and to track outcomes for those whose mutations remain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Florida
Gainesville, Florida, 32608, United States
-
University of Rochester
Rochester, New York, 14642, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.